Sugi Predict

Sugi Predict / Compounds / Orientin

Orientin

Orientin

SCHEMBL10307494

O=c1cc(-c2ccc(O)c(O)c2)oc2c([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]3O)c(O)cc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 6/20 1.00
▸ KDM4E B2RXH2 6/20 1.00
▸ GAA P10253 5/20 1.00
▸ POLB P06746 5/20 1.00
▸ MEN1 O00255 4/20 1.00
▸ KMT2A Q03164 4/20 1.00
▸ TDP1 Q9NUW8 4/20 1.00
▸ APEX1 P27695 4/20 1.00
▸ MAPT P10636 3/20 1.00
▸ ALDH1A1 P00352 3/20 1.00
▸ THRB P10828 1/20 1.00
▸ CYP1A2 P05177 1/20 0.83
▸ AKR1B1 P15121 1/20 0.75
▸ SYNJ2 O15056 1/20 0.67
▸ RECQL P46063 2/20 0.62
▸ NTSR1 P30989 1/20 0.62
▸ HSD17B10 Q99714 1/20 0.60
▸ TNF P01375 1/20 0.60
▸ IL2 P60568 1/20 0.60
▸ AKT1 P31749 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Orientin SCHEMBL30799311 1.00 L3MBTL1 (1.00) L3MBTL1KDM4EGAAPOLBMEN1
Orientin SCHEMBL26230970 1.00 L3MBTL1 (1.00) L3MBTL1KDM4EGAAPOLBMEN1
Orientin SCHEMBL22422532 1.00 L3MBTL1 (1.00) L3MBTL1KDM4EGAAPOLBMEN1
Orientin SCHEMBL25942 1.00 L3MBTL1 (1.00) L3MBTL1KDM4EGAAPOLBMEN1
Orientin SCHEMBL29687058 1.00 L3MBTL1 (1.00) L3MBTL1KDM4EGAAPOLBMEN1
Orientin SCHEMBL13059270 1.00 L3MBTL1 (1.00) L3MBTL1KDM4EGAAPOLBMEN1
Orientin SCHEMBL2216066 0.91 L3MBTL1 (0.83) L3MBTL1KDM4EGAAPOLBMEN1
Vitexin SCHEMBL29572351 0.91 L3MBTL1 (1.00) L3MBTL1KDM4EGAAPOLBMEN1
Vitexin SCHEMBL25277 0.91 L3MBTL1 (1.00) L3MBTL1KDM4EGAAPOLBMEN1
Vitexin SCHEMBL10013309 0.91 L3MBTL1 (1.00) L3MBTL1KDM4EGAAPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3763419-A1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES Anji Pharma (US) LLC (US) 2021-01-13 — — EP disclosed
EP-2661266-B1 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES ANJI PHARMA (US) LLC (US) 2020-09-16 — — EP disclosed
US-10610500-B2 Chemosensory receptor ligand-based therapies ANJI PHARMA (US) LLC (US) 2020-04-07 — — US disclosed
US-20190038576-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2019-02-07 — — US disclosed
US-9962344-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2018-05-08 — — US disclosed
US-9962344-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2018-05-08 — — US disclosed
US-20170020829-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2017-01-26 — — US disclosed
US-20170020829-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2017-01-26 — — US disclosed
US-9463170-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2016-10-11 — — US disclosed
US-9463170-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2016-10-11 — — US disclosed
US-20150265555-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2015-09-24 — — US disclosed
US-20150265555-A1 Chemosensory Receptor Ligand-Based Therapies ANJI PHARMACEUTICALS INC. 2015-09-24 — — US disclosed
US-9050292-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2015-06-09 — — US disclosed
US-9050292-B2 Chemosensory receptor ligand-based therapies ELCELYX THERAPEUTICS, INC. (US) 2015-06-09 — — US disclosed
US-20140030332-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2014-01-30 — — US disclosed
US-20140030332-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2014-01-30 — — US disclosed
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — US disclosed
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies ELCELYX THERAPEUTICS, INC. (US) 2012-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120177730-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 L3MBTL1 2860/4885KDM4E 4211/4885GAA 1625/4885
US-10610500-B2 Chemosensory receptor ligand-based therapies TAS1R2, TAS2R1, GPR119 L3MBTL1 2860/4885KDM4E 4211/4885GAA 1625/4885
US-20150265555-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 L3MBTL1 2860/4885KDM4E 4211/4885GAA 1625/4885
US-20170020829-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 L3MBTL1 2860/4885KDM4E 4211/4885GAA 1625/4885
US-20190038576-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 L3MBTL1 2860/4885KDM4E 4211/4885GAA 1625/4885
US-20140030332-A1 Chemosensory Receptor Ligand-Based Therapies TAS1R2, TAS2R1, GPR119 L3MBTL1 2860/4885KDM4E 4211/4885GAA 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.